How long should I take the targeted drug Lynparza tablets, and what should I pay attention to?

Olaparib tablets are a drug containingolaparib, which belongs to the poly(ADP-ribose) polymerase (PARP) inhibitor category and mainly acts on the three enzymes PARP1, PARP2 and PARP3. PARP enzymes play important roles in normal cellular functions, especially in DNA transcription and DNA repair processes. Lynparza is a targeted therapy that preferentially kills cancer cells by exploiting defects in the DNA damage response (DDR) pathway, such as BRCA mutations, providing new treatment hope for cancer patients carrying these specific gene mutations.

As for the treatment duration of Lynparza Tablets, it mainly depends on the patient's specific condition and the doctor's evaluation. For first-line maintenance treatment of advanced ovarian cancer with BRCA gene mutations, patients usually need to continue treatment until disease progression, unacceptable toxicity, or completion of a two-year treatment cycle. If the patient achieves complete remission (i.e., no imaging evidence of disease) after two years, treatment should be discontinued. However, treatment can be extended beyond two years if the patient still has evidence of disease after two years and the treating physician believes continued treatment may benefit the patient.

For the first-line maintenance treatment of HRD-positive advanced ovarian cancer combined with bevacizumab, the principle of using olaparib tablets is similar, that is, treatment is continued until disease progression, unacceptable toxicity occurs, or the two-year treatment cycle is completed. Likewise, if the patient achieves complete remission after two years, treatment should be discontinued; otherwise, treatment may be continued based on the evaluation of the treating physician.

For adjuvant treatmentof BRCA gene mutation HER2-negative high-risk early breast cancer, the treatment duration of Lynparza Tablets is usually one year, or until the disease relapses or unacceptable toxicity occurs, whichever occurs first. At the same time, patients receiving treatment for hormone receptor-positive HER2-negative breast cancer should continue to receive endocrine therapy in accordance with current clinical practice guidelines.

For other indications, such as hereditary BRCA mutated recurrent ovarian cancer, hereditary BRCA mutated HER2-negative metastatic breast cancer, hereditary BRCA mutated metastatic pancreatic cancer, and HRR gene mutated metastatic castration-resistant prostate cancer, treatment with Lynparza tablets is usually continued until disease progression or unacceptable toxicity occurs.

While taking Lynparza tablets, patients need to pay attention to the following points:

1. Strictly follow the doctor’s instructions: take the dosage and medication time prescribed by the doctor, and do not adjust the dosage or stop taking the medication on your own.

2. Regular monitoring: Regularly conduct blood tests and other necessary medical examinations to evaluate the efficacy and possible side effects of the drug.

3. Note on side effects: Lynparza tablets may cause some side effects, such as nausea, vomiting, fatigue, anemia, etc. If serious or persistent side effects occur, inform your doctor promptly.

4. Avoid specific foods: You should avoid drinking grapefruit juice or eating grapefruit while taking Lynparza tablets, because these foods may affect the metabolism and efficacy of the drug.

5. Inform doctor about other drug use: Patients should inform their doctor if they are using other drugs, including prescription drugs, over-the-counter drugs, and supplements, to avoid drug-drug interactions.

6. Family planning: For female patients of childbearing age, effective contraceptive measures should be taken while taking Lynparza tablets, and contraception should be continued for a period of time after stopping the medication.

In short, Lynparza tablets, as a targeted therapeutic drug, play an important role in the treatment of cancers with specific genetic mutations. However, the length of treatment and medication precautions need to be determined based on the patient's specific condition and the physician's assessment. During the period of taking it, patients should strictly follow the doctor's instructions, monitor regularly, pay attention to side effects, and communicate with the doctor in a timely manner to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.drugs.com/pro/lynparza.html#s-43684-0